Clinical Trial Update: SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan [EARLY_Phase 1]

View source ↗

Summary

This early-phase trial plan explores the cardiovascular benefits of SGLT2 inhibitors and ketone strategies in people with type 2 diabetes and heart failure with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Type 2 Diabetes Mellitus

Drugs mentioned

• Ketone-based therapy
• SGLT2 inhibitors (SGLT2 inhibitor)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Type2 Diabetes, Heart Failure With Preserved Ejection Fraction | EARLY_Phase 1 | Status: RECRUITING